Merck wants to beef up its immunology pipeline through additional deals, the Big Pharma’s chief medical officer Eliav Barr said at an Endpoints News event on Tuesday.
“We’ll be looking for those immunology opportunities that we think can complement or add a new facet to things,” Barr said.
The big pharma, which houses the best-selling cancer medicine Keytruda, has invested substantially in immunology in recent years, including a $10.8 billion buyout of Prometheus last year. That deal gave Merck an experimental treatment for inflammatory bowel diseases and firmly moved the company into the immunology field.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.